William W Winder
Pharmacy in Provo, UT
License number
Utah 4806663-8911
Category
Pharmacy
Type
Pharmacist Controlled Substance
Address
Address
Provo, UT
Personal information
See more information about William W Winder at radaris.comName
Address
Phone
368 S 200 E, Blanding, UT 84511
3826 W 8920 S, West Jordan, UT 84088
4943 S Murray Blvd APT Y34, Salt Lake City, UT 84123
612 Eastridge Dr, Tooele, UT 84074
2265 N 4575 W, Ogden, UT 84404
Professional information
Method Of Treatment Of Obesity And Paralyzed Muscle And Ergogenic Aids
US Patent:
2003021, Nov 13, 2003
Filed:
Dec 2, 2002
Appl. No.:
10/297117
Inventors:
William Winder - Provo UT, US
International Classification:
A61K031/7076
US Classification:
514/047000
Abstract:
The invention relates to a method of treating obesity in a mammal. The method includes the step of administering a therapeutically effective amount of an AMP-activated protein kinase activator to the mammal. The mammal may be for example, a human, a rat, a mouse, and the like. The AMP-activated protein kinase activator can be subcutaneously injected into the mammal or administered in any other manner that provides for uptake of the AMP-activated protein kinase activator into the cells of the mammal. The activation of the AMP-activated protein kinase activator can produce the benefits of exercise training including the loss of body fat. The invention also relates to a method of treating insulin resistance in a mammal suffering from obesity, type 2 diabetes, or muscle paralysis. To reduce the insulin resistance a therapeutically effective amount of an AMP-activated protein kinase activator is given to the mammal.
Use Of Amp Kinase Activators For Treatment Type 2 Diabetes And Insulin Resistance
US Patent:
2003021, Nov 13, 2003
Filed:
Dec 3, 2002
Appl. No.:
10/297114
Inventors:
William Winder - Provo UT, US
International Classification:
A61K031/7056, A61K031/7076
US Classification:
514/043000, 514/047000
Abstract:
A method of treating type 2 diabetes in a mammal is provided. The method includes the step of administering a therapeutically effective amount of an AMP-activated protein kinase activator to the mammal. The mammal may be for example, a human, a rat, a mouse, and the like. The AMP-activated protein kinase activator can be subcutaneously injected into the mammal or administered in any other manner that provides for uptake of the AMP-activated protein kinase activator into the cells of the mammal. The activation of the AMP-activated protein kinase activator can produce the benefits of exercise training including the translocation of GLUT4 in the muscle cells of the mammal. A method of treating insulin resistance in a mammal is also provided. To treat the insulin resistance a therapeutically effective amount of an AMP-activated protein kinase activator is given to the mammal.